Please login to the form below

Not currently logged in
Email:
Password:

Diabetes drug development data announced

Boehringer's linagliptin demonstrates reduction of blood glucose in phase III as Novo Nordisk's degludec achieves proof-of-concept at phase II

Boehringer Ingelheim's linagliptin, a dipeptidyl peptidase (DPP)-4 inhibitor under investigation as a once-daily oral treatment against type 2 diabetes, achieved clinically meaningful reductions in blood glucose, according to phase III study data presented at the 70th Scientific Sessions of the American Diabetes Association (ADA).

In four multicentre, 24-week, randomised, double-blind trials, linagliptin's blood glucose reductions were significant versus placebo and sustained over the study periods. The compound, which has a primarily non-renal route of excretion, is being investigated as a monotherapy and in combination with metformin, with pioglitazone and with voglibose, which is not licensed in the UK.

Also at the ADA meeting, Novo Nordisk presented phase II proof-of-concept data for its investigational insulin degludec, an ultra-long-acting basal insulin, which demonstrated the potential to help achieve target glycaemic control (similar to insulin glargine) when used once-daily or three-times-weekly.

Insulin degludec, a novel insulin molecule with a distinct ultra-long clinical profile, is believed to slow the absorption rate of the insulin into the blood. This leads to a longer profile of action and the possibility of a three-times-weekly dosing regimen in patients with type 2 diabetes. Insulin degludec will now be investigated in the pivotal phase III BEGIN and BOOST trials.

28th June 2010

Share

Subscribe to our email news alerts

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
By offering patients knowledge, skills and confidence, they empower patients to be more actively involved in their health. Holistic support can help tackle adherence, mental health or anything else patients...
THE EVOLVING ROLE OF PROCUREMENT?
Procurement is evolving to reinforce its position as a strategic enabler of company growth. How can agency partners organisations to realise this?...